SORMAIN, which was terminated early because of slow accrual, demonstrated that sorafenib maintenance could reduce the risk of relapse and death after allo-HSCT for patients with FLT3-ITD AML, with the 2-year overall survival (OS) of 90.5% and 66.2% in the sorafenib and placebo groups [36]. The gene discussed is FLT3; the disease is acute myeloid leukemia.